Cellenkos is a clinical-stage biotech based in Houston, Texas focused on developing transformative allogeneic Treg cell therapies to treat autoimmune and inflammatory disorders. Its proprietary CRANE™ platform generates tissue-directed, activated and enriched Treg cells that seek, localize, proliferate and resolve tissue inflammation. Lead products include CK0802, a lung-homing umbilical cord blood–derived Treg therapy for Acute Respiratory Distress Syndrome (ARDS), and CK0804, a bone marrow–homing allogeneic Treg subpopulation for myelofibrosis. The company’s cord blood–derived Treg therapeutic platform is licensed from the University of Texas MD Anderson Cancer Center. Cellenkos was founded by Simrit Parmar, MD of MD Anderson and Golden Meditech Holdings Limited and operates an in-house cGMP facility enabling large-scale manufacturing where multiple doses can be generated from a single umbilical cord blood unit. Its off-the-shelf allogeneic cell products are cryopreserved and available on-demand for infusion at the point of care. Proceeds from the financing will be used to further development of its Treg cell therapy platform.

Total raised

$15M

Funding rounds

1

Latest round

Series A

Latest activity

Nov 2021